Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo

BACKGROUND: Many patients with diabetes mellitus (DM) require a combination of antidiabetic drugs with complementary mechanisms of action to lower their hemoglobin A(1c )levels to achieve therapeutic targets and reduce the risk of cardiovascular complications. Linagliptin is a novel member of the di...

Descripción completa

Detalles Bibliográficos
Autores principales: Horie, Yoshiharu, Hayashi, Naoyuki, Dugi, Klaus, Takeuchi, Masahiro
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743680/
https://www.ncbi.nlm.nih.gov/pubmed/19732457
http://dx.doi.org/10.1186/1745-6215-10-82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743680/
https://www.ncbi.nlm.nih.gov/pubmed/19732457
http://dx.doi.org/10.1186/1745-6215-10-82

Ejemplares similares